Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

1999

Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999;104(6):R13-8.

Brady SP, Magro CM, Diaz-Cano SJ, Wolfe HJ. Analysis of clonality of atypical cutaneous lymphoid infiltrates associated with drug therapy by PCR/DGGE. Hum Pathol. 1999;30(2):130-6.

Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999;163(1):194-205.

Cesarman E, Mesri EA. Virus-associated lymphomas. Curr Opin Oncol. 1999;11(5):322-32.

Walsh S, Murphy M, Silverman M, Odze R, Antonioli D, Goldman H, et al. p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis. Am J Pathol. 1999;155(5):1511-8.

Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J. 1999;18(11):3044-53.

Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin. 1999;17(3):537-60, viii.

Bao S, Chang MS, Auclair D, Sun Y, Wang Y, Wong WK, et al. HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res. 1999;59(9):2023-8.

1998

Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem. 1998;273(37):24057-64.

Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 1998;157(4 Pt 1):1093-7.